The report surveyed payers around the world to better understand their perspective on the COVID-19 pandemic and what it could mean for the industry. ZS conducted 45-minute surveys with 25 global health plans from March 30 to April 7.
Here are the 10 therapy areas U.S. payers said they are prioritizing right now, ranked from highest to lowest:
1. Vaccines
2. Anti-infectives
3. Oncology
4. Cell and gene therapy
5. Biosimilars
6. Acute care medicines
7. Autoimmune diseases
8. Orphan diseases
9. Generics
10. Medical devices
Access the full report here.
More articles on payers:
UnitedHealth to give members $1.5B in discounts
Humana waives costs for primary care, behavioral health visits for 4.5 million members
Health Care Service Corp. taps new CEO
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.